| Document |
Document Title |
|
JP4097294B2 |
The present invention describes a method for treating neuropathic pain comprising administering to a mammal afflicted with such condition a therapeutically effective amount for treating such condition of a compound of formula (I), wherei...
|
|
JP4086314B2 |
Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or es...
|
|
JP2008101020A |
To provide a composition and a method useful for treating amyloidosis.A therapeutic compound and a method for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by th...
|
|
JP4073787B2 |
An enzyme which decomposes a sulfated fucoglucuronomannan and is useful in the field of glycotechnology; a process for producing the enzyme; a fucoidan fraction reduced in the number of the kinds of molecules and useful as a reagent in g...
|
|
JP2008505897A |
Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for us...
|
|
JPWO2005095428A1 |
The present invention provides a bacterium having a functional substance on its surface and a method for producing the same. In particular, it is an object of the present invention to produce such a bacterium having good intestinal absor...
|
|
JPWO2005095427A1 |
A composition for the prevention or treatment of thrombosis, which comprises a low molecular weight product of a sulfated fucose-containing polysaccharide and / or a pharmacologically acceptable salt thereof.
|
|
JPWO2005092348A1 |
In the present invention, a uronic acid residue (uronic acid indicates iduronic acid or glucuronic acid; hereinafter the same applies to uronic acid) and a glucosamine residue are α1,4-glycoside bond or β1,4-glycoside bond. 2 sugars, o...
|
|
JP2008500372A |
Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a va...
|
|
JP4023848B2 |
Disclosed is a method for producing a sulfated lactosamine oligosaccharide, comprising the step of allowing a sulfotransferase to act on a lactosamine oligosaccharide, the sulfotransferase transferring sulfate group to hydroxyl group at ...
|
|
JP4007760B2 |
Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): foods, drinks, cosmetics, etc. containing as the active ingredient at least one member se...
|
|
JP4009318B2 |
Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are met...
|
|
JP3991043B2 |
|
|
JP2007217316A |
To provide an immunopotentiator containing an industrially producible phosphorylated saccharide composition containing glucose, oligosaccharide and dextrin which are not bonded with phosphate-group. The immunopotentiator comprises a comp...
|
|
JP3967769B2 |
PCT No. PCT/EP94/03852 Sec. 371 Date Sep. 11, 1996 Sec. 102(e) Date Sep. 11, 1996 PCT Filed Nov. 17, 1994 PCT Pub. No. WO95/14026 PCT Pub. Date May 26, 1995The invention relates to beta (1->6) glucosamine disaccharides having general for...
|
|
JP2007195401A |
To provide a method for producing a phosphoric ester of a saccharide or a saccharide derivative which is simple and new as compared with conventional methods. The method for producing the phosphoric ester of the saccharide or saccharide ...
|
|
JP2007521255A |
The present invention is based, at least in part on the discovery of therapeutic agents capable of preventing, inhibiting or modulating abnormal processing, misfolding or aggregation of protein. The therapeutic agents of the invention ma...
|
|
JP2007515434A |
The invention relates to compounds that are designed to mimic the structure of GAGs; methods for the preparation of the compounds; compositions comprising the compounds; and use of the compounds and compositions thereof for the anti-angi...
|
|
JP3930556B2 |
PCT No. PCT/GB93/00541 Sec. 371 Date Aug. 24, 1994 Sec. 102(e) Date Aug. 24, 1994 PCT Filed Mar. 16, 1993 PCT Pub. No. WO93/18777 PCT Pub. Date Sep. 30, 1993.Mannose-6- and 1-phosphates and their pharmaceutically acceptable salts and bio...
|
|
JP3918953B2 |
PURPOSE: To provide a tunable bisconjugate that comprises two saccharides which contain a plurality of monosaccharide units, at least one unit being uronic acid, and a spacer, and the spacer links one saccharide to the other saccharide a...
|
|
JP2007070403A |
To provide a pH adjusting agent having pH buffer ability equal or superior to that of an inorganic phosphate in the neutral to acid region, not affecting taste/flavor, and little in causing the adverse effect of calcium absorption inhibi...
|
|
JP3893057B2 |
A codon comprising one or more artificial bases so as to form a selective base pair with the use of steric hindrance and/or electrostatic repulsion, and stacking action at the base moiety of a nucleic acid; a nucleic acid comprising the ...
|
|
JP3890537B2 |
To obtain an antiinflammatory agent having an excellent secretin- inhibiting action, an excellent antiinflammatory action and an excellent cancer metastasis-inhibiting action, low in cytotoxicity, and acting on inflammations such as pneu...
|
|
JP2007039341A |
To provide low-molecular fucoidan-derived low-molecular compounds causing little problems related to absorbency, antigenicity, uniformity, anticoagulation activity, etc., having a specified structure and functions and produced when fucoi...
|
|
JP2007008899A |
To provide a vascularization inhibiting composition containing a low-molecular-weight polysaccharide containing sulfated fucose and provide a medicine or food containing the composition.A composition containing a polysaccharide containin...
|
|
JP3865411B2 |
PURPOSE: To obtain the subject new anti-endotoxin compound useful for treating activation through a lipopolysaccharide (LPS) which serves as a medium for septic shocks, viral infectious diseases, etc. CONSTITUTION: The objective compound...
|
|
JP2006342168A |
To provide a method with which high-quality trehalose derivatives (ethers or esters) as a safe surfactant useful as a food and drink, a cosmetic, a medicine, etc., can inexpensively be produced in good yield.The method for producing the ...
|
|
JP3854063B2 |
To obtain a sulfated fucogalactan decomposable enzyme and to provide a method for obtaining an enzymatically produced sulfated fucogalactan oligosaccharide. This sulfated fucogalactan is useful as a reagent for sugar chain engineering or...
|
|
JP2006306882A |
To provide a new nucleotide analog exhibiting an antitumor/antineoplastic activity, an antimicrobial activity of a wide spectrum and other desired activities.The invention provides a compound of formula: B-Z-PO(-L1)-L2 wherein -Z- is exe...
|
|
JP2006290898A |
To provide a compound of formula I, wherein L1 and L2 are each independently an amino acid or polypeptide residue bound to the phosphorus atom of the compound through an amidate bond, or an oxyester, a thioester, a substituted or un-subs...
|
|
JP2006523715A |
The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and an alkylating-type antineoplastic agent.
|
|
JP3830999B2 |
To obtain a new compound useful as an intermediate for deoxyfluoro-β-cytidine, which is an antiviral agent and an anticancer agent, and capable of giving β-anomer or β-anomer nucleoside in a higher yield than α-anomer. A compound of ...
|
|
JP3827017B2 |
A process and catalyst composition are provided for the highly efficient enantioselective hydrogenation of dehydroamino acid derivatives. The catalyst composition comprises rhodium or iridium and a diphosphinite carbohydrate ligand, wher...
|
|
JP2006182779A |
To provide a nucleotide analog compound having antiviral activity.A compound represented by formula Ib, its stereoisomer and salt have antiviral activity (wherein, X1 indicates O or S; # indicates a carbon having optical activity; B indi...
|
|
JP2006514071A |
The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.
|
|
JP3769045B2 |
PURPOSE: To easily obtain an anti-inflammatory agent virtually free from side effects, having sufficient anti-inflammatory action, containing, as active ingredi ent, a sulfated chitinoligosaccharide. CONSTITUTION: This anti-inflammatory ...
|
|
JP3762445B2 |
PURPOSE: To provide a novel compound, useful as an intermediate for synthesizing 2'-deoxynucleosides having the anti-virus activity and the anti-neoplasm activity. CONSTITUTION: A compound represented by formula I, (wherein R2 is H or a ...
|
|
JP2006502234A |
The present invention relates to the treatment of dyskinesia with compounds of General Formula (I) such as topiramate. The compound may be topiramate or a derivative thereof. The dyskinesia may be associated with a basil ganglia-related ...
|
|
JP2005536493A |
This invention relates to processes for production of alkylamino glucosaminide phosphate compounds, and of disaccharide compounds, including various novel intermediates and intermediate processes. In one aspect, glycosyl halides are prod...
|
|
JP2005272433A |
To provide a hyaluronic acid-producing accelerator which has a hyaluronic acid production-accelerating action and exhibits an excellent effect on acceleration of wound healing.The hyaluronic acid-producing accelerator comprises phytic ac...
|
|
JP2005529838A |
A process is described for preparing a substrate for the transglycosylase enzymes of bacterial cell wall biosynthesis. The chemical synthesis makes available a sustainable and substantially pure source of supply of lipid II, including an...
|
|
JP2005527498A |
A process and cosmetic preparation for skin augmentation of a subject comprising an active component comprising a 1,4 linked D-glucose oligosaccharide or polysaccharide wherein after delivery, the oligosaccaharide or polysaccharide cause...
|
|
JP2005524645A |
The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutica...
|
|
JP3666818B2 |
Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic co...
|
|
JP3659989B2 |
PURPOSE: To stereoselectively obtain β-anomer enriched 2-deoxy-2,2-difluoro-D- ribofuranosyl-3,5,-hydroxy protected-1-alkyl and aryl sulfonate intermediates comparatively easily which are useful in the preparation of anticancer compound...
|
|
JP2005512965A |
Anticonvulsant derivatives useful for treating restless limb syndrome, more particularly restless legs syndrome, restless arms syndrome, periodic limb movement disorder and associated sleep disturbances, regardless of underlying cause.
|
|
JP2005510453A |
Provided are compounds and compositions thereof that are useful for treating inflammation, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such com...
|
|
JPWO2002103025A1 |
Sulfated sugars represented by the following general formula are described. [A]-(6SO3-GlcNAc)-[C] -R (in the formula, (6SO3-GlcNAc) indicates a 6-sulfated N-acetylglucosamine residue, [A] indicates a hydroxyl group or a sugar residue. [C...
|
|
JP3623236B2 |
Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic co...
|
|
JP3621097B2 |
The present invention relates to a method of preparing BCH-189 and various analogues of BCH-189 from inexpensive precursors with the option of introducing functionality as needed. This synthetic route allows the stereoselective preparati...
|
